According to inhalation CDMO Vectura, the company been granted planning permission to build a new £58 million, 10,000 sq m facility in Southwest England to house the company’s Inhalation Centre of Excellence, with construction expected to be completed in 2025. The company said that it aims for the building on the Bristol & Bath Science Park to receive a BREEAM Excellent rating and suggests that the new facility “will create an optimal environment for innovation to support the development of important new inhaled treatments and wellness products.”
In March 2021, Vectura announced that it was adding a new semi-automatic DPI filling and assembly line at its facility in Chippenham, UK. The company also added a laboratory for handling highly potent APIs at the Chippenham facility in 2021.
Vectura CEO Michael Austwick commented, “We are delighted that our plans to build a world-leading science facility have been approved by South Gloucestershire Council. The new-build will enable our already successful pharmaceutical company to continue and expand upon its vital work, providing innovative inhalation and other advanced drug delivery solutions that have the potential to improve the lives of patients around the world. For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide. This new facility will help us to build on this successful track record, increasing workspace capacity and attracting talent to the area.”
Read the Vectura press release.
